Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05860569 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Primary completion date: Dec 2025 to Dec 2026 Secondary endpoints: 6 to 5v4 Show 1 more changeShow less
    • Secondary endpoints: 6 to 5

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Enrollment target: 12 to 7 · Primary endpoints: 1 to 2 · Start date changed from estimate of Dec 2024 to Sep 20, 2024 · 1 morev3 Show 4 more changesShow less
    • Enrollment target: 12 to 7
    • Primary endpoints: 1 to 2
    • Start date changed from estimate of Dec 2024 to Sep 20, 2024
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  4. Start date: Dec 2023 to Dec 2024v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study will evaluate safety and tolerance of intravenous delivery of GC304 gene therapy drug as a treatment of primary hypertriglyceridemic patients with previous onset of acute pancreatitis.
Trial Details
NCT Number NCT05860569
Lead Sponsor GeneCradle Inc
Conditions Hypertriglyceridemia, Familial
Enrollment 7 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov